Combination therapies with BCL-2/BCL-xL inhibitors, targeting the intrinsic pathway, and JAK inhibitor ruxolitinib have demonstrated synergy in pre-clinical models of adult T-cell leukemia lymphoma and T-ALL [25, 56, 57]. Here, BCL2L1 is linked to adult T-cell leukemia/lymphoma.